Breast cancer surgery reimbursements fell 24% in 20 years: Study
New study reveals significant decline in Medicare reimbursements for common breast cancer surgeries over the past 20 years.
New study reveals significant decline in Medicare reimbursements for common breast cancer surgeries over the past 20 years.
Roughly 11% of active pharmaceutical ingredients produced for the US market were linked to generic drug shortages in 2020 and 2021.
Findings from the phase 3 DESTINY-Breast06 trial will be presented at a future medical meeting and shared with regulatory authorities.
Erin Frances Cobain, MD, highlights the current role of endocrine therapy and CDK4/6 inhibitors in HR-positive, HER2-negative metastatic breast cancer.
OncLive® State of the Science Summit: Disease State, Month Day, Year. Oncology live event features research and clinical advances in oncology.
Trastuzumab deruxtecan enhanced survival without disease progression compared with chemotherapy in HR-positive, HER2-low metastatic breast cancer after 1 or more lines of endocrine therapy.
With the high out-of-pocket costs for cancer care, nearly 60% of working-age cancer survivors report experiencing at least one type of financial hardship, including being…
Programmed cell death protein 1(PD-1) axis blockade has become the mainstay in the treatment of recurrent and/or metastatic (R/M) head and neck squamous cell cancer…
In this Article of the month podcast, Annals of Oncology Editor in Chief Tom Powles talks to Prof. Amanda Psyrri, of the National Kapodistrian University…
Nature Cancer – Lawson et al. show that genetic inactivation of Phd1 or Phd2 hinders progression of AML and compromises leukemic stem cells. They develop…
Nature Cancer – Ye and colleagues show that an oncolytic virus that delivers tumor-irrelevant bystander T cell epitopes to tumor cells can exploit the abundant…